617O Lemzoparlimab, a differentiated anti-CD47 monoclonal antibody, in combination with azacitidine (AZA) in patients with newly diagnosed higher risk myelodysplastic syndrome (HR-MDS): Initial clinical results

Z Xiao,R Fu,A Zhu,H Tong,X Ma,Q Li,T Qin,C Chang,Y He,Q Wang,J Li,X Yan,M Dai,L Gu,X Wei,W Huang,Y Meng,Y Zhang,S Gao,J Weng

doi:10.1016/j.annonc.2022.07.743

617O Lemzoparlimab, a differentiated anti-CD47 monoclonal antibody, in combination with azacitidine (AZA) in patients with newly diagnosed higher risk myelodysplastic syndrome (HR-MDS): Initial clinical results

Z Xiao, R Fu + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.743

Copy DOI

Journal: Annals of Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

#Higher Risk Myelodysplastic Syndrome #Initial Clinical Results + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Lemzoparlimab (TJ011133) is a differentiated CD47 antibody targeting a distinct epitope to enable a unique red blood cell sparing property while retaining strong anti-tumor activity. We report initial data in an ongoing phase 2 trial in HR-MDS (NCT04202003).

Full Text